Metastatic Bladder Urothelial Carcinoma (IMvigor210 Phase II Trial, ESMO Open. 2024) - iAtlas Harmonized

Summary

Metastatic Bladder Urothelial Carcinoma (IMvigor210 Phase II Trial, ESMO Open. 2024) - iAtlas Harmonized is a study catalogued by cBioPortal DataHub under the cancer-type code blca. EvidenceHelix groups it with kidney and bladder studies.

Study description

Whole-exome sequencing and neoantigen landscape analysis of 347 metastatic bladder urothelial carcinomas and their matched normals, generated from a phase II trial of atezolizumab monotherapy in cisplatin-ineligible and platinum-pretreated patients. The reprocessing of raw sequencing data is coordinated by CRI iAtlas (https://cri-iatlas.org/).

Text as published in the source's study metadata.

Citation & PubMed

Rosenberg et al. ESMO Open 2024

Linked PubMed records: PMID 39642637, PMID 27939400

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

blca_iatlas_imvigor210_2017

Short name

not given

Source cancer-type code

blca

Reference genome

hg38

Source access groups

not given

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Rosenberg et al. ESMO Open 2024

• PubMed record 39642637 ↗
• PubMed record 27939400 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• Bladder Urothelial Carcinoma (BGI, Nat Genet 2013)

  Whole-exome and whole-genome sequencing of 99 bladder cancer tumor/normal pairs. Generated by BGI.

  Kidney and bladderOther published and consortium studiesSource code blcaPubMed 1

• Urothelial Carcinoma (BCAN/HCRN, Nat Commun 2022)

  Urothelial Cancer-GENOmic analysis to improve patient outcomes and research.

  Kidney and bladderOther published and consortium studiesSource code blcaPubMed 1

• Urothelial Carcinoma (Cornell/Trento, Nat Gen 2016)

  Whole-exome sequencing of 72 tumor samples (with 32 matched normals) in Urothelial Carcinoma.

  Kidney and bladderOther published and consortium studiesSource code blcaPubMed 1

• Bladder Cancer (MSK, Eur Urol 2014)

  Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. Targeted sequencing of 109 tumor samples (MSKCC, European Urology 2014).

  Kidney and bladderMSK studiesSource code blcaPubMed 1

• Bladder Cancer (MSK, J Clin Onco 2013)

  Comprehensive profiling of 97 high-grade bladder tumors, including targeted sequencing of 15 cancer genes

  Kidney and bladderMSK studiesSource code blcaPubMed 1

• Bladder Cancer (MSK, Nat Genet 2016)

  Whole exome and targeted sequencing of 34 plasmacytoid-variant (signet ring cell) tumors of the bladder

  Kidney and bladderMSK studiesSource code blcaPubMed 1

• Bladder Cancer (MSK/TCGA, 2020)

  Whole-exome or targeted sequencing of 476 muscle-invasive bladder tumor/normal pairs via TCGA or MSK-IMPACT sequencing.

  Kidney and bladderTCGA (other releases)Source code blcaPubMed 1

• Bladder Cancer (TCGA, Cell 2017)

  Whole-exome sequencing of 412 muscle-invasive bladder tumors and matched normal samples.

  Kidney and bladderTCGA (other releases)Source code blcaPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.